Enclomiphene Citrate for Secondary Hypogonadism: Evidence, Risks, and Trade-offs

Enclomiphene citrate is the purified trans-isomer of clomiphene citrate, taken as a compounded oral capsule to raise a man's own testosterone by blocking estrogen receptors in the hypothalamus and pituitary. It has no FDA-approved indication for male hypogonadism as of 2025, so every prescription is off-label and every capsule comes from a compounding pharmacy rather than a manufacturer with FDA-inspected quality control. The reason it gets prescribed anyway is narrow and specific: for a man with secondary (hypothalamic-pituitary) hypogonadism who wants to father a child, standard testosterone replacement therapy shuts down sperm production, while enclomiphene's mechanism raises the same gonadotropins that testosterone therapy suppresses. That trade-off, not a claim that enclomiphene is a better testosterone drug overall, is the actual clinical question this page addresses.

The core answer, and its boundary

In men with confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH and FSH), enclomiphene citrate raises serum testosterone by removing estrogen's negative feedback on the pituitary, and trial reports describe this happening in the majority of treated men over three to six months, without the drop in sperm count typically seen with testosterone gel. It is not FDA-approved for this or any use, it does not work in primary (testicular) hypogonadism, and no controlled trial has followed patients long enough to establish cardiovascular or bone safety. That combination, real short-term hormonal effect plus an off-label, unregulated-supply, unknown-long-term-safety profile, is the trade-off a prescriber and patient are actually weighing.

Why it exists as an off-label option

Standard testosterone replacement therapy (TRT) suppresses the hypothalamic-pituitary-testicular axis. Exogenous testosterone tells the hypothalamus and pituitary that enough androgen is present, so GnRH, LH, and FSH output falls, intratesticular testosterone drops, and spermatogenesis declines. For a man in his 20s or 30s with secondary hypogonadism who wants children in the near term, TRT is often the wrong first move for that specific goal, even though it remains an effective and FDA-approved way to raise testosterone in men who do not need to preserve fertility.

Enclomiphene was developed to fill that gap by working upstream of the testes, at the level of the brain's feedback sensors, rather than by supplying testosterone directly. Repros Therapeutics pursued FDA approval for enclomiphene (branded Androxal) through the mid-2010s; the agency did not approve the application, reportedly citing concerns about long-term cardiovascular safety data and the trial design used to support the comparator claims. Readers and editors should treat the exact dates and letter-by-letter FDA rationale as needing verification against primary regulatory correspondence; what is confirmed by the FDA's own approvals database is that enclomiphene does not currently appear as an approved drug for any indication (FDA Drug Approvals and Databases, checked January 2025). Because no approval exists, all current use in men comes from compounding pharmacies, which are not held to the same manufacturing and batch-consistency standards as an approved drug product.

What is established, what is plausible, and what is not established

Established, from trial reports and mechanism:

• Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary, which increases GnRH pulsatility and downstream LH and FSH secretion.
• In men with secondary hypogonadism, this mechanism raises serum testosterone in the short to medium term (weeks to months) in sponsor-reported trials.
• The mechanism does not restore testosterone in primary hypogonadism, where the testes themselves cannot respond adequately to higher LH.
• Enclomiphene has no FDA-approved indication as of 2025 and is available only through compounding.

Plausible but not proven by controlled data:

• That enclomiphene preserves fertility better than TRT over a full attempt-to-conceive timeline; the trial data on sperm parameters are short-duration surrogate measures, not live-birth or time-to-pregnancy outcomes.
• That enclomiphene is meaningfully safer or better tolerated than generic clomiphene in men, since a well-powered head-to-head randomized trial in this population has not been established from the sources reviewed here.
• That combining enclomiphene with an aromatase inhibitor for estradiol control is safe and effective long-term; this pairing is used clinically but rests on case-level experience rather than trial evidence.

Not established:

• Long-term cardiovascular outcomes with enclomiphene.
• Effects on bone density.
• Whether benefits or hormonal patterns persist with multi-year use, or whether the axis behaves normally after stopping.

How the mechanism works

Secondary hypogonadism, also called hypogonadotropic hypogonadism, originates above the testes: testosterone is low while LH and FSH are low or inappropriately normal, meaning the hypothalamus or pituitary is not sending an adequate signal. Circulating estradiol, produced from testosterone through aromatase, normally feeds back on hypothalamic estrogen receptors to restrain GnRH pulse frequency. Enclomiphene occupies those receptors without activating them, which removes the brake, increases GnRH pulses, and raises pituitary LH and FSH output. Higher LH drives Leydig cell testosterone production; higher FSH supports Sertoli cell function, which underlies sperm production.

This is the same basic mechanism used by clomiphene citrate, which has been prescribed off-label for male hypogonadism for decades. The distinction is isomer purity, described in the next section.

Because the entire mechanism depends on testes that can still respond to gonadotropin stimulation, a baseline LH and FSH panel is essential before considering enclomiphene. Elevated LH and FSH alongside low testosterone points to primary (testicular) hypogonadism, where more gonadotropin stimulation will not fix a Leydig cell that has already failed, and enclomiphene as monotherapy would not be an appropriate treatment choice in that setting.

What the trial evidence shows, and where it needs verification

The strongest published evidence for enclomiphene comes from Repros Therapeutics' Phase II and Phase III program, generally referenced in the literature as the ZA-201 and ZA-301 trials, which compared enclomiphene 12.5 mg and 25 mg once daily against topical testosterone gel and, in some arms, placebo, in men with secondary hypogonadism.

Reported directional findings, described qualitatively here because the specific enrollment counts, percentages, and p-values inherited from earlier source material could not be independently confirmed in this review:

• Both enclomiphene doses raised morning serum testosterone into the normal range for most participants over the trial period, with an effect broadly comparable to topical testosterone gel.
• Sperm concentration declined in the testosterone gel arm over the study period, consistent with the known HPTA-suppressing effect of exogenous testosterone.
• Sperm concentration was reported as preserved or increased in the enclomiphene arms over the same period.
• LH and FSH remained within or near the normal range on enclomiphene, while they were suppressed on testosterone gel, which is the expected mechanistic signature of each drug.
• Estradiol rose in all testosterone-raising arms, roughly in proportion to the testosterone increase, which follows from aromatase converting more substrate as testosterone rises.

A retrospective, single-clinic chart review of compounded enclomiphene use has also been described in the literature, reporting testosterone increases and a low rate of documented adverse events; retrospective, unblinded chart reviews carry inherent limitations (no control arm, no blinding, selection and follow-up bias) and should be weighed accordingly, well below randomized trial evidence in the hierarchy.

The FDA's decision not to approve enclomiphene was reportedly driven less by a lack of short-term efficacy signal and more by the absence of a dedicated long-term cardiovascular safety study and by trial-design questions, a pattern that matters for how a patient should interpret "the drug works" versus "the drug is approved."

Decision framework: which pathway fits a given man's situation

This is not a substitute for an individualized evaluation, which requires a clinician to review a specific man's testosterone, LH, FSH, prolactin, fertility timeline, symptoms, and medical history. It is a structured way to see which broad pathway the evidence supports investigating further, and what would change the answer.

Enclomiphene versus clomiphene citrate

Clomiphene citrate (available generically) is FDA-approved only for ovulation induction in women, but has been used off-label in men for hypogonadism since long before enclomiphene existed. Clomiphene is a mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a much longer half-life than enclomiphene and accumulates with daily dosing, and it has been described as having partial estrogen-agonist activity in some tissues, which is the theoretical argument for why isolating the trans-isomer might reduce estrogenic side effects such as mood changes or gynecomastia. Pharmacokinetic comparisons supporting this accumulation pattern exist in the literature; the exact study parameters should be confirmed against the primary paper before being quoted with specific numbers.

In practice, generic clomiphene costs a small fraction of compounded enclomiphene per month. Whether enclomiphene's cleaner isomer profile translates into a clinically meaningful difference in side effects or efficacy for men has not been demonstrated by a head-to-head randomized trial in the material reviewed here. That gap is worth stating plainly to a patient who is deciding whether the added cost is justified.

Enclomiphene versus TRT versus hCG

Endocrine Society guidance on male hypogonadism has generally advised against testosterone therapy as a first choice in men who are currently trying to conceive, favoring approaches that stimulate the man's own gonadotropin axis instead. That general guideline stance, rather than any single quoted sentence, is the accountable-body evidence behind the fertility-preservation niche for enclomiphene, clomiphene, and hCG.

Human chorionic gonadotropin (hCG) is a subcutaneous injection that mimics LH directly at the Leydig cell, raising testosterone and helping maintain testicular volume, but it does not raise FSH, so its effect on sperm production is reported as less consistent than approaches (like enclomiphene or clomiphene) that raise both gonadotropins. No head-to-head randomized trial comparing hCG and enclomiphene was identified in the sources reviewed for this page.

Reasonable candidates for enclomiphene or a related SERM approach include men with secondary hypogonadism who are actively trying to conceive or plan to within roughly two years, men who want to avoid testicular atrophy, and men whose hypogonadism may be linked to a reversible contributor such as obesity, untreated sleep apnea, or opioid use. Reasonable candidates for TRT instead include men with primary hypogonadism (where the mechanism does not apply), men with no fertility goal who want the most predictable and best-studied path to symptom relief, and men who do not respond adequately to enclomiphene after an adequate trial at studied doses.

How dosing and monitoring have been approached in practice

No FDA-approved prescribing information exists for enclomiphene, so there is no official dosing label. Trials studied 12.5 mg and 25 mg orally once daily; doses above 25 mg daily have not been evaluated in controlled trials. The following describes the general shape of monitoring used in published protocols and clinical practice, not an individualized dosing instruction. Any specific starting dose, titration, and monitoring interval should come from a treating clinician who has reviewed a patient's own labs and history.

A general monitoring framework reported in practice includes a baseline panel (total testosterone, LH, FSH, estradiol, prolactin, complete blood count, metabolic panel, and semen analysis if fertility is a goal), a repeat hormone panel around four to six weeks after starting or adjusting the dose, a fuller panel including lipids around twelve weeks, and periodic full panels roughly every six months thereafter, with prompt ophthalmologic evaluation if any visual symptoms occur. Duration of treatment in the pivotal trials was limited to roughly three to six months; real-world use often extends well beyond that window, and whether benefits, hormone patterns, or axis sensitivity remain stable over years of use is not established.

Risks, side effects, and contraindications

Visual disturbances. Blurred vision, light sensitivity, and scotomas have been reported in a small percentage of trial participants and are considered the most serious reported adverse effect, generally reversible on stopping the drug. Any new visual symptom on enclomiphene warrants immediate discontinuation and prompt ophthalmologic evaluation; this is not a symptom to monitor and wait out.

Estradiol elevation and gynecomastia. Because enclomiphene raises testosterone, and aromatase converts a portion of that testosterone to estradiol, estradiol rises roughly in proportion. Gynecomastia has been reported in a minority of trial participants, with higher body fat (more aromatase activity) plausibly increasing risk. Adding an aromatase inhibitor is used clinically when estradiol rises with symptoms, but this combination has not itself been studied in a controlled trial and carries its own uncertainty.

Mood and libido changes. Estrogen-receptor blockade in the central nervous system, the same general mechanism responsible for mood effects seen with tamoxifen, can produce irritability, mood lability, or reduced libido in some men. Reported rates in the sponsor's trials were low, though real-world reports from less closely monitored compounded use suggest this may be underrecognized outside a trial setting.

Lipid effects. Clomiphene has been associated with HDL cholesterol reductions in some reports; enclomiphene's lipid effects are not well characterized because no dedicated long-term lipid trial exists. Baseline and periodic lipid monitoring is a reasonable precaution.

Contraindications and situations requiring caution: primary hypogonadism (elevated LH/FSH with low testosterone), known hypersensitivity to clomiphene or enclomiphene, significant active liver disease, pre-existing retinal or visual disorders, concurrent use of medications that meaningfully inhibit CYP3A4, and untreated pituitary macroadenoma or prolactinoma, where stimulating LH/FSH output before addressing the underlying lesion could obscure disease progression.

If a man on enclomiphene develops sudden vision loss, severe headache with visual changes, or signs suggestive of a pituitary mass (new visual field loss, severe headache, galactorrhea), that warrants urgent medical evaluation rather than routine follow-up.

What informed consent should cover

Because enclomiphene is off-label and compounded, informed consent needs to do more work than it would for an approved drug. A reasonable consent conversation covers: that enclomiphene has no FDA-approved indication for male hypogonadism; that a New Drug Application was pursued and not approved, with long-term cardiovascular safety data cited as a gap; that compounded product is not subject to the same manufacturing oversight as an approved drug, so batch-to-batch potency can vary; that visual disturbances require immediate discontinuation and evaluation; that fertility preservation is a plausible and mechanistically supported benefit but has not been proven with pregnancy or live-birth outcomes in controlled trials; and that long-term effects on the axis, bone, and cardiovascular system are unknown.

Frequently asked questions

References and verification notes

The Repros Therapeutics Phase II and Phase III trials (publicly referenced as ZA-201 and ZA-301), the clomiphene-versus-enclomiphene pharmacokinetic literature, and the Endocrine Society hypogonadism guidelines are the evidentiary backbone of this page. The specific PubMed identifiers and quoted figures attached to these studies in earlier drafts of this article could not be independently confirmed during this review and have been removed rather than carried forward as verified links, consistent with treating inherited citations as unverified until checked against the original journal record. Before publication, an editor or clinician with database access should confirm: the exact enrollment numbers and percentage outcomes for the Phase II and III enclomiphene trials, the specific FDA Complete Response Letter dates and stated rationale, the precise wording of the Endocrine Society's fertility-related recommendation, and the source of any statement attributed by name to a specific guideline author.

• U.S. Food and Drug Administration, Drug Approvals and Databases (used here only to support the general statement that enclomiphene has no current FDA approval, checked January 2025): https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases

This article discusses off-label and compounded drug use. It is not a substitute for individualized medical evaluation, diagnosis, or dosing guidance from a licensed clinician who has reviewed a patient's own history and laboratory results.